In vitro and in vivo studies have shown that lonidamine potentiates the cytotoxic effect of anthracyclines in simultaneous and sequential combination. On the basis of such evidence, we evaluated the activity and toxicity of a combination of epirubicin plus lonidamine in advanced breast cancer.
Methods
Between January 1991 and November 1993, 33 patients with advanced breast cancer, age <75 years and PS <2, were treated with epirubicin (75 mg/m2 i.v. on day 1, every 3 weeks), plus lonidamine (450 mg/day orally from day 1 continuously until disease progression).
Results
Thirty patients were evaluable for response: 4 achieved complete response (13%) and 8 partial response (27%) (total response rate = 40%), 6 (20%) had stabilization of disease, and 12 (40%) progression of disease. The median duration of response was 10 months (range, 4-24+ months). This scheme was tolerated, with a mild additional toxicity related to lonidamine: only WHO grade III myalgia in 1 patient (3%) and epigastralgia in 3 patients (9%).
Conclusions
Although some patients seem to have benefited from the combination at the dose levels of the drug used in the study, the therapeutic advantages of addition of lonidamine remain unclear.
BandP.R., MarounJ., PritchardK., StewardD., CoppinC.M., WilsonK., EisenhauerE.: Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.Cancer Treat. Rep.,70: 1305–1310, 1986.
2.
BellelliA., BellelliL., Di PalmaM., LorenzonI., MattioniM., NistaA., PaveseI., RusconiV., SezziM.L.: Effects of VM26 and lonidamine on a B16 melanoma cell line.Anticancer Res.,10: 565–578, 1990.
3.
CalabresiF., MarollaP., Di LauroL., Gallo CurcioC., PaolettiG., LombardiA., GiannarelliD., BallatoreP., FoggiC.M., Di PalmaM., StolfiR., CortesiE.: Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study.Int. J. Oncol.,4: 753–760, 1994.
4.
CitroG., CuccoC., VerdinaA., ZupiG.: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.Br. J. Cancer,64: 534–536, 1991.
5.
Del BufaloD., ZupiG.: In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell lines.Int. J. Oncol.,4: 737–740, 1994.
6.
De MartinoC., MalorniW., AccinniL., RosatiF., NistaA., FormisanoG., SilvestriniB., AranciaG.: Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells.Exp. Mol. Pathol.,46: 15–30, 1987.
7.
DogliottiL., BerrutiA., BunivaT., ZolaP., BaùM.G., FarrisA., SarobbaM.A., BottiniA., AlquatiP., DeltettoF., GossoP., MonzeglioC., MoroG., SussioM., PerroniD.: A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from cooperative group study.Int. J. Oncol.,4: 747–752, 1994.
8.
FloridiA., PaggiM.G., D'AtriS., De MartinoC., MarcanteM.L., SilvestriniB., CaputoA.: Effect of lonidamine on the energy metabolism of Erlich ascites tumor cells.Cancer Res.,41: 4661–4666, 1981.
9.
FloridiA., PaggiM.G., MarcantiM.L., SilvestriniB., CaputoA., De MartinoC.: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.J. Natl. Cancer Inst.,66: 497–499, 1981.
GardinG., BaroneC., NascimbenO., IannielloG., SturbaF., ContuA., PronzatoP.: Lonidamina + epirubicina e ciclofosfamide (LND + EC) nel carcinoma mammario metastatico (CMM): studio di fase II (Abst.).Tumori,79(3, Suppl.): 48, 1993.
12.
MansiJ.L., De GraeffA., NewellD.R., GlaholmJ., ButtonD., LeachM.O., PayneG., SmithI.E.: A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer.Br. J. Cancer,64: 593–597, 1991.
13.
NeriB., LottiniG., BandinelliE., Cini-NeriG.: Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart.Anticancer Drugs,2: 401–404, 1991.
14.
PloskerG.L., FauldsD.: Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.Drugs,45: 788–856, 1993.
15.
PronzatoP., AmorosoD., BertelliG., ConteP.F., CusimanoM.P., CiottoliG.B., GulisanoM., LionettoR., RossoR.: Phase II study of lonidamine in metastatic breast cancer.Br. J. Cancer,59: 251–253, 1989.
16.
RobinsH.I., NeubergD.S., BensonA.B.III, PandyaK.J., TormeyD.C.: Phase II study of lonidamine in patients with metastatic breast cancer.Invest. New Drugs,8: 397–399, 1990
17.
Robustelli della CunaG., PedrazzoliP.: Toxicity and clinical tolerance of lonidamine.Semin. Oncol.,18: 18–22, 1991.
18.
RosbeK.W., BrannT.W., HoldenS.A., TeicherB.A., FreiE.III: Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.Cancer Chemoter. Pharmacol.,25: 32–36, 1989.
19.
RossiV., JovicevicL., Capezzone de JoannonA., CaricatoL., Di CastroV., De MartinoC.: In vitro effects of lonidamine and teniposide on three human tumor cell lines.J. Exp. Clin. Cancer Res.,10: 221–241, 1991.
20.
RossoR., AmorosoD., GardinG., MigliettaL., GuidoT., PaceM., RepettoL., PronzatoP.: Lonidamine in metastatic breast cancer.Semin. Oncol.,18: 62–65, 1991.
21.
SanguedolceR., FlandinaC., CucchiaraT., VarvaraF., RausaL.: Morphological changes in the hearts of CD I mice following chronic treatment with doxorubicin and lonidamine.Res. Commun. Chem. Pathol. Pharmacol.,82: 81–89, 1993.
22.
SaviniS., ZoliW., NanniO., VolpiA., FrassinettiG.L., MagniE., FlamigniA., AmadoriA., AmadoriD.: In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res.Treat.,24: 27–34, 1992.
23.
SilvestriniR., ZaffaroniN., VillaR., OrlandiL., CostaA.: Enhancement of cisplatin activity by lonidamine in human ovarian cells.Int. J. Cancer,52: 813–817, 1992.
24.
TeicherB.A., HoldenS.A., HermanT.S., FreiE.III: Modulation of alkylation agents by lonidamine in vivo.Semin. Oncol.,18: 7–10, 1991.
25.
TeicherB.A., HermanT.S., HoldenS.A., EpelbaumR., LiuS., FreiE.III: Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.Cancer Res.,51: 780–784, 1991.
26.
TomirottiM., BernardoG., EpifaniC., BiasioliR., FranchiR., MensiF., CarnaghiP., SchieppatiG., ScanniA.: Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients.Int. J. Oncol.,3: 213–217, 1993.
27.
World Health Organization:WHO handbook for reporting the results of cancer treatment.WHO offset publication no. 48, Geneva, 1979.
28.
ZupiG., GrecoC., LaudonioN., BenassiM., SilvestriniB., CaputoA.: In vivo and in vitro potentiation by lonidamine of the antitumor effect of adriamycin.Anticancer Res.,6: 1245–1250, 1986.
